SCHEMBL3669397

SCHEMBL3669397

CCCCCn1c(O)nc2ncc(O)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
TLR8 Q9NR97 8/20 0.39
HTT P42858 1/20 0.35
HTR1A P08908 6/20 0.34
DRD1 P21728 6/20 0.34
DRD4 P21917 6/20 0.34
DRD5 P21918 6/20 0.34
DRD3 P35462 6/20 0.34
TP53 P04637 2/20 0.34
CNR2 P34972 1/20 0.34
DRD2 P14416 5/20 0.33
ESR1 P03372 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3671478 0.88 TLR8 (0.45) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3668520 0.86 TLR8 (0.39) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3666329 0.86 TLR8 (0.37) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3668135 0.86 TLR8 (0.37) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3668582 0.86 TLR8 (0.37) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3678311 0.86 PSEN1 (0.40) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3670686 0.85 TLR8 (0.36) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3670730 0.85 TLR8 (0.36) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3672331 0.85 PDE6A (0.42) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3667095 0.85 PSEN1 (0.39) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP claimed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 ALDH1A1 4750/4885KDM4E 4360/4885MEN1 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.